SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc., a privately held biotechnology company, announced a collaboration with Mayo Validation Support Services to investigate a test featuring a select panel of tumor-specific genes to aid in patient risk stratification and assist in chemotherapy treatment decisions for breast cancer patients. The test uses gene expression profiling to predict recurrence of malignancy in patients diagnosed with primary invasive early stage breast cancer.
